Profile data is unavailable for this security.
About the company
Biora Therapeutics, Inc. is a biotechnology company, which is focused on creating smart pills designed for targeted drug delivery to the gastrointestinal (GI) tract, and systemic, needle-free delivery of biotherapeutics. The Company’s pipeline includes two therapeutic delivery platforms: NaviCap and BioJet. The NaviCap, targeted oral delivery platform, which is designed to improve outcomes for patients with inflammatory bowel disease through treatment at the site of disease in the gastrointestinal tract. The BioJet, systemic oral delivery platform, which is designed to replace injection for better management of chronic diseases through needle-free, oral delivery of large molecules. It has two demonstration drug-device combination programs for the BioJet platform, BT-200 (GLP-1 receptor agonist) and BT-002 (adalimumab variant). Its other two programs include BT-600 (NaviCap + tofacitinib) and BT-001 (NaviCap + variant of adalimumab) for the treatment of ulcerative colitis.
- Revenue in USD (TTM)892.00k
- Net income in USD-35.57m
- Incorporated2012
- Employees58.00
- LocationBiora Therapeutics Inc4330 La Jolla Village Drive, Suite 200SAN DIEGO 92122United StatesUSA
- Phone+1 (760) 494-1555
- Fax+1 (248) 848-1623
- Websitehttps://www.bioratherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adial Pharmaceuticals Inc | 0.00 | -13.03m | 6.53m | 4.00 | -- | 1.11 | -- | -- | -4.49 | -4.50 | 0.00 | 0.9185 | 0.00 | -- | -- | 0.00 | -272.04 | -182.35 | -316.95 | -235.45 | -- | -- | -- | -- | -- | -16.22 | 0.00 | -- | -- | -- | 35.14 | -- | -- | -- |
| Transcode Therapeutics Inc | 0.00 | -14.93m | 6.56m | 10.00 | -- | 3.97 | -- | -- | -8.49 | -8.49 | 0.00 | 0.0957 | 0.00 | -- | -- | 0.00 | -210.77 | -133.14 | -475.23 | -181.26 | -- | -- | -- | -- | -- | -40.02 | 0.00 | -- | -- | -- | -5.59 | -- | -- | -- |
| Brainstorm Cell Therapeutics Inc | 0.00 | -14.23m | 6.59m | 29.00 | -- | -- | -- | -- | -3.46 | -3.46 | 0.00 | -1.14 | 0.00 | -- | -- | 0.00 | -369.22 | -117.19 | -- | -231.65 | -- | -- | -- | -- | -- | -35.87 | -- | -- | -- | -- | 29.18 | -- | -45.34 | -- |
| NLS Pharmaceutics AG | 0.00 | -6.60m | 6.66m | 3.00 | -- | -- | -- | -- | -6.72 | -6.72 | 0.00 | -9.40 | 0.00 | -- | -- | 0.00 | -380.82 | -272.62 | -- | -- | -- | -- | -- | -- | -- | -27.20 | -- | -- | -- | -- | 26.21 | -- | -- | -- |
| National Graphite Corp | 0.00 | -1.97m | 6.79m | 0.00 | -- | -- | -- | -- | -0.0221 | -0.0221 | 0.00 | -0.0193 | 0.00 | -- | -- | -- | -11,014.44 | -212.13 | -- | -6,295.18 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -1,432.70 | -- | -- | -- |
| Edesa Biotech Inc | 0.00 | -6.93m | 6.85m | 16.00 | -- | 2.39 | -- | -- | -2.21 | -2.21 | 0.00 | 0.8829 | 0.00 | -- | -- | 0.00 | -94.60 | -- | -128.81 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 52.28 | -- | -- | -- |
| Cannabis Bioscience Internatnl Hlgs Inc | 354.91k | -545.87k | 6.86m | 2.00 | -- | -- | -- | 19.33 | -0.00005 | -0.00005 | 0.00003 | -0.0001 | 8.98 | -- | 15.71 | 177,455.00 | -1,381.60 | -- | -- | -- | 87.28 | -- | -153.81 | -- | -- | -2.16 | -- | -- | -21.46 | -- | 36.92 | -- | -- | -- |
| Virpax Pharmaceuticals Inc | 0.00 | -13.24m | 6.91m | 7.00 | -- | -- | -- | -- | -8.82 | -8.82 | 0.00 | -0.4198 | 0.00 | -- | -- | 0.00 | -198.45 | -87.52 | -594.46 | -116.56 | -- | -- | -- | -- | -- | -128.86 | -- | -- | -- | -- | 29.84 | -- | -- | -- |
| Syros Pharmaceuticals Inc | 386.00k | -97.82m | 6.98m | 68.00 | -- | -- | -- | 18.07 | -3.03 | -3.03 | 0.0105 | -0.4145 | 0.0033 | -- | -- | 5,676.47 | -84.04 | -54.44 | -111.15 | -64.32 | -- | -- | -25,340.67 | -772.82 | -- | -179.01 | 1.37 | -- | -33.23 | 37.12 | -73.87 | -- | -27.78 | -- |
| Biora Therapeutics Inc | 892.00k | -35.57m | 7.07m | 58.00 | -- | -- | -- | 7.93 | -12.92 | -11.78 | 0.2163 | -28.99 | 0.0363 | -- | 1.06 | 15,379.31 | -144.59 | -122.84 | -- | -369.01 | -- | -- | -3,988.12 | -415.10 | -- | -- | -- | -- | -98.69 | -87.44 | -154.63 | -- | -53.68 | -- |
| Plus Therapeutics Inc (USA) | 5.73m | -12.89m | 7.08m | 20.00 | -- | -- | -- | 1.24 | -2.42 | -2.42 | 0.988 | -0.8775 | 0.5653 | -- | -- | 286,250.00 | -127.22 | -59.18 | -- | -133.04 | -- | -- | -225.07 | -470.45 | -- | -4.31 | -- | -- | 2,093.30 | -5.89 | 34.32 | -- | 3.77 | -- |
| ABVC Biopharma Inc | 509.80k | -8.24m | 7.14m | 16.00 | -- | 0.8363 | -- | 14.00 | -0.9744 | -0.9744 | 0.0508 | 0.6576 | 0.0328 | -- | 1.60 | 31,862.50 | -56.14 | -103.38 | -88.09 | -231.54 | 72.54 | 76.25 | -1,710.03 | -2,019.89 | -- | -2.62 | 0.1856 | -- | -84.28 | 85.39 | 35.97 | -- | -- | -- |
| Intelligent Bio Solutions Inc | 3.19m | -10.42m | 7.19m | 13.00 | -- | 1.18 | -- | 2.26 | -27.94 | -27.94 | 1.42 | 1.39 | 0.3121 | 1.93 | 5.56 | 245,228.50 | -102.35 | -71.59 | -255.70 | -144.36 | 48.31 | -- | -327.90 | -565.48 | 1.01 | -- | 0.0775 | -- | 147.58 | 596.39 | 4.47 | -- | -- | -- |
| Cardio Diagnostics Holdings Inc | 35.69k | -8.25m | 7.57m | 7.00 | -- | 2.04 | -- | 212.12 | -0.3853 | -0.3853 | 0.0016 | 0.1215 | 0.0068 | -- | 4.94 | 5,098.57 | -158.03 | -- | -229.86 | -- | -- | -- | -23,124.35 | -- | -- | -27.40 | 0.00 | -- | 1,696.84 | -- | -79.72 | -- | -- | -- |
| Vincerx Pharma Inc | 0.00 | -27.03m | 7.60m | 42.00 | -- | 0.8825 | -- | -- | -1.03 | -1.03 | 0.00 | 0.2901 | 0.00 | -- | -- | 0.00 | -131.14 | -- | -200.57 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 36.24 | -- | -- | -- |
Data as of Nov 22 2024. Currency figures normalised to Biora Therapeutics Inc's reporting currency: US Dollar USD
61.04%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Athyrium Capital Management LPas of 07 Oct 2024 | 2.57m | 58.21% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 69.73k | 1.58% |
| Geode Capital Management LLCas of 30 Sep 2024 | 15.63k | 0.35% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 30 Sep 2024 | 14.48k | 0.33% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 2024 | 6.86k | 0.16% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 6.16k | 0.14% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 5.16k | 0.12% |
| HRT Financial LP (US)as of 30 Sep 2024 | 3.38k | 0.08% |
| XTX Markets LLCas of 30 Sep 2024 | 2.12k | 0.05% |
| LPL Financial LLCas of 30 Sep 2024 | 2.07k | 0.05% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
